生物公司将收购Apellis以加强免疫学和罕见疾病组合. Biogen to acquire Apellis to boost immunology and rare disease portfolio.

生物公司宣布计划收购Apelis, 这一举措旨在加强其免疫学和罕见疾病组合. Biogen Inc. has announced plans to acquire Apellis, a move aimed at boosting its immunology and rare disease portfolio. 预计这笔交易将加强公司的增长前景,并加速其进入脏病市场. The deal is expected to strengthen the company's growth outlook and accelerate its expansion into the nephrology market.